If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 21 - 30 of 299
STRIDE II: A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo Aspiration System II
Objective
Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus
Protocol No
VIR-PENUMBRA-CLP3000-STRIDEII
Categories
ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
Objective
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Protocol No
ALLIANCE-A012303-SHORTSTOP
Categories
Precision Neuromodulation in Post-Stroke Aphasia Using TMS
Objective
Post-Stroke Aphasia TMS - TaMS
Protocol No
NEURO-IIT-SHAH-TAMS
Categories
A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis
Objective
Best Available Therapy vs Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis
Protocol No
NEURO-ITN-077I-BEAT-MS
A Phase 3 Randomized, Open-Label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Next-Generation Hormonal Agent (NHA) and Tax
Objective
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Protocol No
MERCK-MK-5684-003
Categories
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Participants with Chronic Rhinosinusitis with Nasal Polyps on Background Intranasal Corticoste
Objective
Lebrikizumab vs. Placebo w/ Steroids in CRSwNP
Protocol No
OTO-ELILILLY-J2T-MC-KGBU
Categories
A Phase Ib Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients with Relapsed/Refractory Multiple Myeloma
Objective
Study of talquetamab in patients with R/R multiple myeloma
Protocol No
IIT-AKHTAR-CILTA-TALQ
Categories
A Modular Phase II, Single-Arm, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)
Objective
We are doing this study to learn more about the experimental treatment AZD0486, to learn if the study drug will be safe, tolerable and effective in treating the type of lymphoma that you have.
Protocol No
AZ-D7404C00001-SOUNDTRACK-B
Categories
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk: A Randomized Trial
Objective
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
Protocol No
SURG-NHLBI-LEADER-PAD
A Phase 3, Open-Label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)
Objective
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer
Protocol No
MERCK-MK-2400-001
Categories